Browse studies

Find your next paid study

7 recruiting studies matching your filters

A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease

Background: Sickle cell disease (SCD) is an inherited blood disorder. The disease affects the ability of red blood cells to carry oxygen. Research has shown t…

Sickle Cell Disease, Hemolytic Anemia

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Heart, Lung, and Blood Institute (NHLBI)NCT07566494

Phase 1

A Phase 1/2 Dose Evaluation Trial of the Safety and Preliminary Efficacy of Anti CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleuce…

Warm Autoimmune Hemolytic Anemia (WAIHA)ITP - Immune ThrombocytopeniaWarm Autoimmune Hemolytic Anemia+1 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

CRISPR Therapeutics AGNCT07549698

Phase 2

A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA)

The purpose of this study is to evaluate the safety and efficacy of Zola-cel (BMS-986353), in participants with chronic immune thrombocytopenia (cITP) and auto…

Chronic Immune ThrombocytopeniaAutoimmune Hemolytic Anemia

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT07603557

Phase 1

A Phase 1b/2a, Open-label Study of Velinotamig for the Treatment of Adults With Relapsing and Refractory Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia

A Phase 1b/2a, open-label dose escalation and dose expansion study of subcutaneously (SC) administered velinotamig for the treatment of adults with relapsing a…

Immune Thrombocytopenia (ITP)Warm Autoimmune Hemolytic Anemia (WAIHA)

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Cullinan Therapeutics Inc.NCT07738822

Congenital Hemolytic and Dyserythropoietic Anemias

The main reason for this research study is to further understand how some red blood cells are formed incorrectly or they have an abnormal metabolism in a way t…

Hemolytic Anemia

Estimated

~$10 – $675

Actual pay is set by the research site.

Children's Hospital Medical Center, CincinnatiNCT07649213

Phase 3

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

The primary objective of this study is: • To evaluate the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).

Warm Antibody Autoimmune Hemolytic Anemia

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Rigel PharmaceuticalsNCT04138927

Phase 1

An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Autoimmune Cytopenias

An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cyt…

AIHA - Warm Autoimmune Hemolytic AnemiaAIHA - Cold Autoimmune Hemolytic AnemiaITP - Immune Thrombocytopenia

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Lakefront Biotherapeutics West LLCNCT07083960